Natalie Callander, MD
University of Wisconsin 
Interview Date: September 30, 2019

Cancer cells have a different thickness of cell membrane than normal cells. A new treatment is exploiting that difference by delivering a targeted therapy to just the cancer cells while avoiding the normal cells. Cellectar is developing a new treatment called CLR 131, which is a compound that allows the delivery of a radioactive iodine to enter specifically into tumor cells. Radioactive iodine has been used for many years to treat thyroid cancer and has a long history of safety and a short half-life. Dr. Callander describes how this is being used in multiple myeloma and other blood cancers to treat relapsed disease. 

Thanks to our episode sponsor